Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors
Overview
- Phase
- Phase 1
- Intervention
- Cyclophosphamide
- Conditions
- Malignant Brain Neoplasm
- Sponsor
- City of Hope Medical Center
- Enrollment
- 18
- Locations
- 3
- Primary Endpoint
- Incidence of adverse events
- Status
- Recruiting
- Last Updated
- last month
Overview
Brief Summary
This phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to treatment (refractory). Cellular immunotherapy (IL13(EQ)BBzeta/CD19t+ T cells) are brain-tumor specific cells that may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many patients with brain tumor respond to treatment, but then the tumor starts to grow again. Giving chemotherapy in combination with cellular immunotherapy may kill more tumor cells and improve the outcome of treatment.
Detailed Description
PRIMARY OBJECTIVE: I. To assess the feasibility and safety of lymphodepleting chemotherapy followed by cellular immunotherapy utilizing IL13Ralpha2-specific hinge-optimized 41BB-co-stimulatory chimeric antigen receptor \[CAR\] truncated CD19-expressing autologous T-lymphocytes (IL13\[EQ\]BBzeta/CD19t+ Tn/mem cells) administered by intraventricular (ICV) delivery for pediatric participants with IL13Ralpha2+ recurrent/refractory brain tumors. SECONDARY OBJECTIVES: I. To describe persistence and expansion of CAR T cells in peripheral blood (PB) and cerebrospinal (CSF). II. To describe cytokine levels (PB, and CSF) over the study period. III. In research participants who receive the full schedule of 4 CAR T cell cycles: IIIa. To estimate 6-month progression free survival (PFS) rate per disease. IIIb. To estimate disease response rates per disease. IIIc. To estimate 1-year overall survival rate per disease. IV. To evaluate the use of circulating tumor deoxyribonucleic acid (ctDNA) to evaluate tumor burden. V. For study participants who undergo an additional biopsy/resection or autopsy: Va. To evaluate CAR T cell persistence in the tumor tissue and the location of the CAR T cells with respect to the infusion site. Vb. To evaluate IL13Ralpha2 antigen expression levels on tumor tissue pre and post CAR T cell therapy. OUTLINE: This is a dose-escalation study of IL13(EQ)BBzeta/CD19t+ T cells. Patients receive cyclophosphamide intravenously (IV) on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes once a week (QW) on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion. After completion of study treatment, patients are followed for up at 30 days, 3, 6, 9, and 12 months, and then yearly for 15 years.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Documented informed consent of the participant and/or legally authorized representative.
- •Assent, when appropriate, will be obtained per institutional guidelines
- •Agreement to allow the use of archival tissue from diagnostic tumor biopsies
- •Karnofsky Performance Status (KPS) \>= 60% except for loss of mobility due to disease involvement; e.g., confinement to a wheelchair due to spinal cord compression
- •Life expectancy \> 4 weeks
- •Participant has a prior histologically-confirmed malignant brain neoplasm and has progressed after prior conventional therapy
- •Radiographic evidence of progression/recurrence of the measurable disease more than 12 weeks after the end of the initial conventional therapy (including initial radiation therapy)
- •City of Hope (COH) clinical pathology confirms IL13Ralpha2+ tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score \>= 50)
- •If the participant has a shunt, it must be programmable and the participant must be able to tolerate the shunt being switched off for at least 2 consecutive days
- •Platelets \>= 50,000/mm\^3 (performed within 6 weeks of signing the main informed consent)
Exclusion Criteria
- •Pulmonary: Research participant requires supplemental oxygen to keep saturation greater than 95% and the situation is not expected to resolve within 2 weeks
- •Cardiac: Research participant requires pressor support and/or has symptomatic cardiac arrhythmias
- •Renal: Research participant requires dialysis
- •Neurologic: Research participant has uncontrolled seizure activity and/or clinically evident progressive encephalopathy
- •Failure of research participant to understand the basic elements of the protocol and/or the risks/benefits of participating in this phase I study. A legal guardian may substitute for the research participant
- •Research participant with any non-malignant intercurrent illness which is either poorly controlled with currently available treatment, or which is of such severity that the study team deems it unwise to enter the research participant on protocol shall be ineligible
- •Research participant with any other active malignancies
- •Research participant being treated for severe infection or recovering from major surgery is ineligible until recovery is deemed complete by the study team
- •Research participant with any uncontrolled illness including ongoing or active infection. Research participant with known active hepatitis B or C infection; research participant with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections
- •Research participant who has confirmed HIV positivity within 4 weeks of enrollment
Arms & Interventions
Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)
Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
Intervention: Cyclophosphamide
Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)
Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
Intervention: Fludarabine
Treatment (chemotherapy, IL13(EQ)BBzeta/CD19t+ T cells)
Patients receive cyclophosphamide intravenously IV on days -5 and -4, and fludarabine IV on days -5 to -2. Patients then receive autologous IL13(EQ)BBzeta/CD19t+ T cells intraventricularly over 5 minutes QW on day 0. Treatment with autologous IL13(EQ)BBzeta/CD19t+ T cells repeats every 7 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of IL13(EQ)BBzeta/CD19t+ T cells as long as they continue to meet eligibility criteria and have doses available for infusion.
Intervention: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Outcomes
Primary Outcomes
Incidence of adverse events
Time Frame: Up to 1 year after the last chimeric antigen response (CAR) T cell infusion
Will assess the incidence of grade 3 toxicities, dose limiting toxicities, and all other toxicities. Toxicity and adverse events will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 and the revised cytokine release syndrome (CRS) grading system. Symptoms and toxicities will be evaluated by physical exam and blood chemistry/hematology results and adverse event reporting. Rate and associated 90% Clopper and Pearson binomial confidence limits (90% CI) will be estimated for participants experiencing dose limiting toxicities. Tables will be created to summarize all toxicities and side effects by time post treatment, organ, severity and disease subgroup.
Secondary Outcomes
- Persistence and expansion of CAR T cells(Up to 1 year after the last CAR T cell infusion)
- Peripheral blood and CSF cytokine levels(Up to 1 year after the last CAR T cell infusion)
- Overall survival(From time of lymphodepletion to date of death, assessed at 1 year after the last CAR T cell infusion)
- Peripheral blood and CSF immune cell characterization(Up to 1 year after the last CAR T cell infusion)
- Progression free survival(From time of lymphodepletion to the event date (progressionor death), assessed at 6 months)
- Disease response(Up to 1 year after the last CAR T cell infusion)
- CAR T cells detected in tumor tissue(Up to 1 year after the last CAR T cell infusion)
- IL13Ralpha2 antigen expression levels in tumor tissue(Up to 1 year after the last CAR T cell infusion)
- Circulating tumor deoxyribonucleic acid (ctDNA) assessments(Up to 1 year after the last CAR T cell infusion)